Grand Pharmaceutical Group Faces Financial Challenges Amid Valuation Adjustments and Rising Costs

Grand Pharmaceutical Group Ltd., a midcap player in the Pharmaceuticals & Biotechnology sector, has recently undergone an evaluation adjustment that reflects changes in its financial metrics. The stock's valuation score has been revised, indicating a shift in its market position. Key financial indicators reveal a P/E ratio of 16, which positions the company as relatively expensive compared to its peers. The Price to Book Value stands at 1.85, suggesting a notable valuation in the context of its assets. Additionally, the company reports an EV to EBIT of 14.98 and an EV to EBITDA of 12.10, which provide insights into its operational efficiency. Despite a high dividend yield of 306.42%, the company has faced challenges, including a decline in operating profit, which was reported at HKD 997.49 million for the latest quarter. The interest coverage ratio has also reached a low of 1,059.79, indicating potential concerns regarding financial stability. Furthermore, raw material costs have increased by 9.3% year-over-year, impacting overall profitability. In summary, the recent evaluation adjustment for Grand Pharmaceutical Group Ltd. reflects a complex interplay of financial metrics and market conditions. Discover the Latest Mojo Score and Financial Trend Performance - SignUp in less than 2 Minutes and get FREE Premium Access.